Insider · CIK 0001652824
Kenneth T. Mills
Files at RGNX (REGENXBIO Inc.). First filing May 14, 2025, latest May 14, 2025.
In brief
Kenneth T. Mills files SEC Form 4 as director at RGNX (REGENXBIO Inc.). Since May 14, 2025, Kenneth T. Mills has reported 0 open-market buys worth $0 and 1 open-market sell worth $163k, the latest filed on May 14, 2025.
A track record needs three past buys with six months of prices behind them; Kenneth T. Mills has 0, so none is measured yet.
The newest scored trade: sold $163k of RGNX on May 12, 2025, filed May 14, 2025, scored 0 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RGNX: REGENXBIO Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 12, 2025 | RGNX REGENXBIO INC | 20,602 0.04% of outstanding | $155k | May 12, 2025 | none |
| Dec 19, 2023 | RGNX REGENXBIO INC | 45,000 0.10% of outstanding | $878k | Dec 19, 2023 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 495,925 | Jun 2, 2026 |
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| Jan 27, 2026 | RGNX REGENXBIO Inc. | MOption exercise Common Stock | +225,000 | $13.09 | $2.9M | 707,871 | Jan 29, 2026 |
| Jan 27, 2026 | RGNX REGENXBIO Inc. | FTax withholding Common Stock | -221,753 | $13.41 | $3.0M | 486,118 | Jan 29, 2026 |
| Jan 27, 2026 | RGNX REGENXBIO Inc. | MOption exercise Stock Options (Right to Buy)derivative | -225,000 | $0.00 | $0 | 225,000 | Jan 29, 2026 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +7,768 | $0.00 | $0 | 482,871 | Jun 3, 2025 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +39,815 | $0.00 | $0 | 39,815 | Jun 3, 2025 |
| May 12, 2025 | RGNX REGENXBIO Inc. | MOption exercise Common Stock10b5-1 | +20,602 | $3.76 | $77k | 495,705 | May 14, 2025 |
| May 12, 2025 | RGNX REGENXBIO Inc. | SOpen-market sale Common Stock10b5-1 | -20,602 | $7.91 | $163k | 475,103 | May 14, 2025 |
| May 12, 2025 | RGNX REGENXBIO Inc. | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -20,602 | $0.00 | $0 | 0 | May 14, 2025 |
Questions about Kenneth T. Mills
Answered from the filings on this page, as of the latest one.
Is Kenneth T. Mills buying or selling?
Not in the last 12 months. Kenneth T. Mills's latest open-market trade on SEC Form 4 was sold $163k of RGNX on May 12, 2025.
How did Kenneth T. Mills's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kenneth T. Mills has 0.
Where does Kenneth T. Mills file Form 4?
Kenneth T. Mills has filed Form 4 at RGNX (REGENXBIO Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.